RECENTLY PUBLISHED

THE AMERICAN HEART ASSOCIATION/AMERICAN STROKE ASSOCIATION (AHA/ASA) RELEASED UPDATED GUIDELINES ON SECONDARY STROKE PREVENTION, WITH A RECOMMENDATION FOR PFO CLOSURE.

The guidelines state that “it is now considered reasonable to close patent foramen ovale percutaneously in selected patients: those with younger age with nonlacunar stroke or no other cause at any age.”

MAT-2107556 v1.0 | Item approved for Global use.
Skip to main content
Visit patient site
United States

Protect your patients from recurrent stroke

Talisman header

After a PFO-associated stroke, you can significantly reduce your patient's risk of stroke recurrence by referring them for PFO closure.

Learn about the procedure

Preventing a Recurring Stroke Close The Patent Foramen Ovale (PFO)

~25%
About one quarter of ischemic strokes are of unknown cause¹
50%
Nearly half of patients with an ischemic stroke of unknown cause have a PFO²
59%
Patients experience a 59% risk reduction of a recurrent stroke after PFO closure³

Find out how PFO closure might help your patients

The Amplatzer™ Talisman™ PFO Occluder is built off a legacy of excellence, with over 20 years as the market-leading and most-studied PFO device.

Treatment options
PFO Closure
Occluder stroke risk tal 2x

Reduce risk of stroke recurrence

The Amplatzer PFO Occluder was studied in the RESPECT Trial in the US and Canada. The trial enrolled 980 patients, between the ages of 18 to 60, who were diagnosed with a PFO and a cryptogenic stroke. Patients were randomly assigned to receive either the Amplatzer PFO Occluder plus blood-thinning medication, or blood-thinning medication alone.

The RESPECT Trial was designed to evaluate whether PFO closure with the Amplatzer PFO Occluder plus blood-thinning medication was more effective in reducing the risk of another ischemic stroke compared with the sole use of blood-thinning medication. Over a median follow-up period of 5.9 years, the rate of recurrent ischemic stroke was 45% lower with PFO closure compared to medical management exclusively.⁴

In 2020, the American Academy of Neurology (AAN) performed a meta-analysis of 8 randomized controlled trials on PFO closure. The AAN concluded that compared to antiplatelet medication alone, PFO closure plus antiplatelet medication resulted in a 59% risk reduction of recurrent stroke.³

About the Amplatzer Talisman PFO Occluder

Neurologist recommended

With that collaborative spirit [between neurologists and cardiologists]...device placement can occur quite safely and can be HIGHLY effective in reducing stroke with benefits of 50-97% relative reduction in stroke rates.”

— Jeffrey Saver, MD, UCLA Comprehensive Stroke Center

The turning point for PFO Closure

Clinical studies have confirmed the superiority of PFO closure to medical management in reducing the risk of stroke recurrence.³

View the data

Multiple physician societies now recommend PFO closure in select patients.

Read the Guidelines
References
  1. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377:1022-32. doi: 10.1056/NEJMoa1610057
  2. Mojadidi, MK, Zaman MO, Elgendy IY, et al Cryptogenic stroke and patent foramen foramen ovale. J Amer Coll Cardiol. 2018;71:1035-43. doi: 10.1016/j.jacc.2017.12.059
  3. Messé SR, Gronseth GS, Kent DM, et al. Practice Advisory update summary: Patent foramen ovale and secondary stroke prevention. Neurology. 2020;94:876-885. doi: 10.1212/WNL.0000000000009443
MAT-2002569 v3.0 | Item approved for U.S. use only.

You are about to leave pfostroke.com

Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.